Publikationen

Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology

2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)

Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC; a central role of TP53 mutations

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer

Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer

LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells

Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.).

Stratified Treatment in Lung Cancer

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors.

ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology.

Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a TP53 Context-specific Manner.

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. oncology.

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses.

ALK-Diagnostics in NSCLC – Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)

PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Clinicopathological characteristics of RET rearranged lung cancer in European patients

Developments in oncological positron emission tomography/computed tomography assessment

Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.

NOTCH, ASCL1, p53 und RB Änderungen definieren einen alternativen Weg Fahr neuroendokrinen und kleinzelligen Lungenkarzinomen.

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.

Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.

Comprehensive genomic profiles of small cell lung cancer.

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus.

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

PD-L1 expression in small cell neuroendocrine carcinomas.

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.

MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib

CD74-NRG1 Fusions in Lung Adenocarcinoma

Ceritinib in ALK-rearranged non-small-cell lung cancer

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer

A Genomics-Based Classification of Human Lung Tumors

Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small.cell lung cancer

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment

FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications

Activated RET and ROS: two new driver mutations in lung adenocarcinoma

Tumor VEGFR:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

Molecular pathology of the lungs. New perspectives by next generation sequencing

Lung Cancer: Molecular pathology and personalized therapy

Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models

Genetic insight and therapeutic targets in squamous-cell lung cancer

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET

Indications and limitations of fresh frozen sections in the pulmonary apparatus

Comprehensive genomic characterization of squamous cell lung cancers

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer

Early palliative care for patients with metastatic cancer

Predictive value of early and late 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib

Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities

Recommending early integration of palliative care – does it work?

Personalized therapy of lung cancer

The association between active participation in a sports club, physical activity and social network on the development of lung cancer in smokers: a case-control study

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model

Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET

A crucial requirement for Hedgehog signaling in small cell lung cancer

Personalized therapy of lung cancer cokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines

Blood-based gene expression signatures for early detection of lung cancer

Benchmarking of mutation diagnostics in clinical lung cancer specimens

Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL)

Molecular diagnostics of lung cancer for treatment stratification

Focal amplification of FGFR1 associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

Cytohesins Are Cytoplasmic ErbB Receptor Activators

Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium

Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility project

Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors

Identification of lung cancer with high sensitivity and specificity by blood testing

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling

Molekulare Diagnostik

Das Netzwerk Genomische Medizin bietet eine umfassende molekulare Analyse von Tumorproben an. Mittels eines Next Generation Sequencing basierten Multiplex-Verfahrens werden sämtliche therapierelevanten genomischen Veränderungen auch in kleinsten Gewebeproben zuverlässig detektiert.

Zweitmeinung

Haben Sie Fragen zu Ihrer Erkrankung, Ihrer bestehenden Therapie oder vielleicht möchten Sie auch wissen, ob für Sie ein personalisierter Therapieansatz oder eine Immuntherapie in Frage kommt?

Kontaktieren Sie uns!

Klinische Studien

Innerhalb des Netzwerks Genomische Medizin wollen wir allen Patienten mit einer Mutation, für die es noch kein zugelassenes Medikament gibt, eine klinische Studie anbieten.

Informieren Sie sich hier, welche aktuellen Studien es gibt.